Talactoferrin: Phase III data

Data from 94 patients with NSCLC in the discontinued, double-blind, U.S. Phase III FORTIS-C trial showed that twice-daily 1.5 g oral talactoferrin in combination

Read the full 247 word article

How to gain access

Continue reading with a
two-week free trial.